Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-Outcomes
CTR20254568Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM) and 3 more comparing Orforglipron with Placebo (2 arms). Primary endpoint: Time to first MACE-5 composite event. Started Nov 2025; status: active.
02
Drugs
orforglipron
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)heart failure (HF)myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20254568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254568.